Precision BioSciences raises $110 million for off-the-shelf CAR-T and gene-edited crops

by Ryan Cross
July 8, 2018 | APPEARED IN VOLUME 96, ISSUE 28


Precision BioSciences has raised $110 million in series B financing to advance a drug discovery program using Arcus, its homing endonuclease-based gene-editing tool. Homing endonucleases are enzymes, used by scientists years before CRISPR gene editing was invented, that recognize and cut DNA sequences. The Durham, N.C.-based firm will use the funds to move its lead therapy program, off-the-shelf CAR-T cancer treatments, into the clinic and begin field tests of crops edited with Arcus.


This article has been sent to the following recipient:

Leave A Comment

*Required to comment